Drug Trial Radar · NCT04586010
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
746
Actual
Start
Mar 17, 2021
Primary completion
Jan 27, 2026
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study.
Conditions
- Relapsing Multiple Sclerosis
Interventions
FenebrutinibDrug
Participants will receive fenebrutinib.
TeriflunomideDrug
Participants will receive teriflunomide.
PlaceboDrug
Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Minimum of 96 weeks
Locations
158 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Alabama Neurology Associates
Homewood, Alabama
Center for Neurology and Spine - Phoenix - Hunt - PPDS
Phoenix, Arizona
Profound Research, LLC
Carlsbad, California
University of California Irvine
Irvine, California
Quantum Clinical Research, Inc
Pasadena, California
University of Colorado Denver
Aurora, Colorado
Mountain View Clinical Research
Denver, Colorado
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado
Neurology Associates, PA; Research Department
Maitland, Florida
NorthShore University HealthSystem
Highland Park, Illinois
Fort Wayne Neurological Center
Fort Wayne, Indiana
The NeuroMedical Center
Baton Rouge, Louisiana
Ochsner LSU Health
Shreveport, Louisiana
Johns Hopkins University School Of Medicine; Outpatient Center
Baltimore, Maryland
University of Massachusetts Medical School
Worcester, Massachusetts
Henry Ford Health System
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Holy Name Hospital; Institute For Clinical Research
Teaneck, New Jersey
University of New Mexico; MS Specialty Clinic
Albuquerque, New Mexico
Miami Valley Hospital South; Dayton Physician's Office
Centerville, Ohio
OhioHealth
Columbus, Ohio
The Boster Center for Multiple Sclerosis a Singlepoint Healthcare Company
Columbus, Ohio
Oklahoma Medical Research Foundation; MS Center of Excellence
Oklahoma City, Oklahoma
St. Luke's University Health network
Bethlehem, Pennsylvania
Premier Neurology
Greenville, South Carolina
New Orleans Center for Clinical Research
Knoxville, Tennessee
North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
Plano, Texas
Texas Institute for Neurological Disorders
Sherman, Texas
Multiple Sclerosis Center of Greater Washington
Vienna, Virginia
Evergreen MS Center
Kirkland, Washington
Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
Milwaukee, Wisconsin
Neurologia Infantil Buenos Aires (NIBA)
Buenos Aires, Argentina
IME - Instituto Médico Especializado
Buenos Aires, Argentina
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Buenos Aires, Argentina
CIER
C. A. B. A., Argentina
Diagnostico Medico Oroño
Rosario, Argentina
Cer San Juan
San Juan, Argentina
Centro de Investigaciones Médicas Tucuman
San Miguel de Tucumán, Argentina
Peking University First Hospital
Beijing, China
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.